Free Trial
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

Cytek Biosciences logo
$3.36 -0.01 (-0.15%)
As of 02:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cytek Biosciences Stock (NASDAQ:CTKB)

Key Stats

Today's Range
$3.20
$3.39
50-Day Range
$2.42
$3.76
52-Week Range
$2.37
$7.63
Volume
303,623 shs
Average Volume
984,245 shs
Market Capitalization
$426.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.60
Consensus Rating
Hold

Company Overview

Cytek Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

CTKB MarketRank™: 

Cytek Biosciences scored higher than 51% of companies evaluated by MarketBeat, and ranked 510th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cytek Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cytek Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytek Biosciences is -37.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytek Biosciences is -37.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytek Biosciences has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cytek Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    4.14% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently decreased by 6.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cytek Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cytek Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.14% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently decreased by 6.88%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cytek Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for CTKB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytek Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $194,600.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.33% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cytek Biosciences' insider trading history.
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CTKB Stock News Headlines

Cytek Biosciences, Inc. (CTKB): A Bull Case Theory
Genesis 14:13-17 [HIDDEN MEANING?]
A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available.
See More Headlines

CTKB Stock Analysis - Frequently Asked Questions

Cytek Biosciences' stock was trading at $6.49 at the beginning of the year. Since then, CTKB shares have decreased by 48.6% and is now trading at $3.3360.

Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.05. The business earned $41.46 million during the quarter, compared to analyst estimates of $43.18 million. Cytek Biosciences had a negative net margin of 5.71% and a negative trailing twelve-month return on equity of 2.90%.
Read the conference call transcript
.

Cytek Biosciences' Board of Directors authorized a stock buyback program on Monday, December 30th 2024, which allows the company to buy back $50,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 5.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its stock is undervalued.

Cytek Biosciences (CTKB) raised $248 million in an IPO on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

Top institutional shareholders of Cytek Biosciences include Public Employees Retirement System of Ohio (0.05%), State of Alaska Department of Revenue (0.05%), Wealth Enhancement Advisory Services LLC (0.02%) and NorthCrest Asset Manangement LLC (0.01%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, William D Mccombe and Jack Ball.
View institutional ownership trends
.

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
5/08/2025
Today
7/24/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:CTKB
CIK
1831915
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$3.00
Potential Upside/Downside
+67.9%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.02 million
Net Margins
-5.71%
Pretax Margin
-4.05%
Return on Equity
-2.90%
Return on Assets
-2.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.62
Quick Ratio
4.95

Sales & Book Value

Annual Sales
$200.45 million
Price / Sales
2.11
Cash Flow
$0.04 per share
Price / Cash Flow
93.65
Book Value
$3.07 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
126,660,000
Free Float
113,575,000
Market Cap
$422.54 million
Optionable
Optionable
Beta
1.33

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:CTKB) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners